Page 35 - 《中国药房》2025年3期
P. 35

·药学研究·


          活性氧响应型甲氨蝶呤修饰紫杉醇/淫羊藿苷胶束的工艺优化与
          体外抗肿瘤作用评价
                                          Δ


                                                             1
                                                                      1 #
                                   1
                                                     1
                           2
                 1*
                                            1
          邹乃建 ,孔 亮 ,常 雷 ,万芃伯 ,姜晓琳 ,袁明殿 ,鹿英强 (1.辽宁中医药大学附属医院泌尿外科,
          沈阳 110032;2.辽宁中医药大学药学院,辽宁 大连 116600)
          中图分类号  R943;R73-3      文献标志码  A      文章编号  1001-0408(2025)03-0285-08
          DOI  10.6039/j.issn.1001-0408.2025.03.05
          摘  要  目的  制备活性氧(ROS)响应型甲氨蝶呤(MTX)修饰紫杉醇(PTX)/淫羊藿苷(ICA)胶束(MTX-oxi-Ms@PTX/ICA),并
          对其进行工艺优化和体外抗肿瘤作用评价。方法  通过协同毒性实验筛选PTX和ICA的协同毒性浓度范围。采用薄膜水合法制
          备胶束,通过响应面法优化其工艺,并评估按最优工艺制备的胶束的基本特性。考察胶束对小鼠肾癌细胞RENCA的细胞毒性、
          靶向性以及抑制侵袭和迁移的作用。结果  协同毒性实验结果表明,PTX浓度为2.5~10 μmol/L、ICA浓度为5~15 μmol/L时表
          现出最强的协同毒性效果。MTX-oxi-Ms@PTX/ICA的最优工艺如下:聚乙烯己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物(So‐
          luplus )质量为 80 mg,Soluplus 和维生素 E 琥珀酸酯聚乙二醇 1000 质量比为 4∶1(mg/mg),二硬脂酰基磷脂酰乙醇胺-聚乙二醇
              ®
                                 ®
          2000-酮缩硫醇-聚乙二醇5000为2 mg,二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000-甲氨蝶呤为2 mg,PTX为1 mg,ICA为1.5 mg,水
          合温度35 °C,处方量为5 mL。最优工艺条件下,3批MTX-oxi-Ms@PTX/ICA中2个药物的平均包封率为92.75%;其临界胶束浓
          度为 0.007 9 mg/mL,粒径为(62.09±1.68) nm,多分散性指数为 0.046±0.032,Zeta 电位为(-2.47±0.15) mV;放置 30 d 内,胶束
          粒度和多分散性指数均未发生明显变化;体外释放结果表明,MTX-oxi-Ms@PTX/ICA能够在氧化环境中更快地响应并释放药物。
          MTX-oxi-Ms@PTX/ICA对RENCA细胞的半数抑制浓度为(5.170±0.036) μmol/L;体外细胞摄取实验结果表明,与未修饰胶束相
          比,经MTX修饰的胶束对癌细胞具有更强的靶向效果,且其对RENCA细胞侵袭、迁移的抑制能力显著增强(P<0.05)。结论  成
          功制备了MTX-oxi-Ms@PTX/ICA胶束,该胶束具有较高的包封率、较低的临界胶束浓度和良好的稳定性;且其对RENCA细胞有
          较明显的细胞毒性,并具有抑制癌细胞侵袭、迁移的作用。
          关键词  活性氧响应型胶束;甲氨蝶呤;靶向药物递送;紫杉醇;淫羊藿苷

          Technology  optimization  and  in  vitro  anti-tumor  effect  evaluation  of  reactive  oxygen  species-responsive
          methotrexate-modified paclitaxel/icariin micelles
                                   2
                                                1
          ZOU Naijian ,KONG Liang ,CHANG Lei ,WAN Pengbo ,JIANG Xiaolin ,YUAN Mingdian ,LU Yingqiang        1
                                                                                              1
                                                                             1
                     1
                                                              1
         (1.  Dept.  of  Urology  Surgery,  the Affiliated  Hospital  of  Liaoning  University  of  Traditional  Chinese  Medicine,
          Shenyang  110032,  China;2.  School  of  Pharmacy,  Liaoning  University  of  Traditional  Chinese  Medicine,
          Liaoning Dalian 116600, China)
          ABSTRACT   OBJECTIVE  To  prepare  reactive  oxygen  species (ROS)-responsive  methotrexate (MTX)-modified  paclitaxel
         (PTX)/icariin (ICA)  micelles (MTX-oxi-Ms@PTX/ICA),  and  perform  technology  optimization  and  in  vitro  anti-tumor  effect
          evaluation.  METHODS  Synergistic  toxicity  concentration  range  of  PTX  and  ICA  was  screened  by  synergistic  toxicity  test.  The
          micelles  were  prepared  by  thin  film  hydration  method,  and  their  technology  was  optimized  by  response  surface  methodology.  The
          fundamental characteristics of the micelles prepared by the optimal technology were evaluated. The micelles’ cytotoxicity, targeting
          ability  to  renal  carcinoma  RENCA  cells  of  mice,  and  their  inhibitory  effects  on  invasion  and  migration  were  assessed.  RESULTS
          Results  of  synergistic  toxicity  experiments  demonstrated  that  the  strongest  synergistic  effect  occurred  when  PTX  concentrations
          ranged from 2.5 to 10 μmol/L and ICA concentrations ranged from 5 to 15 μmol/L. The optimal technology of MTX-oxi-Ms@PTX/
          ICA was determined to include 80 mg Soluplus , Soluplus  and TPGS1000 mass ratio of 4∶1 (mg/mg), 2 mg DSPE-PEG2000-TK-
                                             ®
                                                     ®
          PEG5000,  2  mg  DSPE-PEG2000-MTX,  1  mg  PTX,  and  1.5  mg  ICA,  with  a  hydration  temperature  of  35  ℃  and  a  formulation
          volume  of  5  mL.  Under  the  optimal  conditions,  average  encapsulation  efficiency  of  PTX  and  ICA  in  3  batches  of  MTX-oxi-
                                                             Ms@PTX/ICA   reached   92.75%,   the   critical   micelle
                                                             concentration (CMC)  was  0.007  9  mg/mL,  the  particle  size
             Δ 基金项目 国家自然科学基金项目(No.82204629)
             *第一作者 主治医师,硕士。研究方向:中西医结合治疗肾病。                   was (62.09±1.68)  nm,  the  polydispersity  index (PDI)  was
          E-mail:zounaijian@126.com                          0.046±0.032, and the Zeta potential was (-2.47±0.15) mV.
             # 通信作者 副主任医师。研究方向:中西医结合治疗肾病。                    Within  30  days  of  placement,  there  was  no  significant  change
          E-mail:yingqiang_1126@163.com                      in  particle  size  and  polydispersity  index  of  micelle.  In  vitro


          中国药房  2025年第36卷第3期                                                 China Pharmacy  2025 Vol. 36  No. 3    · 285 ·
   30   31   32   33   34   35   36   37   38   39   40